Navigation Links
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting
Date:12/12/2011

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced final results from a Phase 2 study, known as the 004 study, evaluating single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma. Results on prolonged infusion of carfilzomib and speed of response were also announced. These data were presented at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

Abstract #813: Final Results from the Bortezomib-Naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Results from the 004 Phase 2 study evaluated single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who had received one to three prior treatments and had not been previously treated with bortezomib. In 67 evaluable patients, carfilzomib achieved an overall response rate (ORR) of 52 percent and a clinical benefit rate (CBR) of 64 percent when administered at 27mg/m(2). Sixty-four percent of patients were refractory to their most recent therapy prior to entering the trial. Overall response is defined as a partial response or greater.[i]  The median time-to-progression (TTP), duration of response (DOR) and overall survival (OS) were not reached in this study, designed to provide patients with up to 12 cycles of carfilzomib.  Forty-two percent of patients completed greater than 10 cycles and 22 patients continued treatment beyond one year in the extension protocol PX-171-010.

"This Phase 2 study demonstrates promising single-agent activity of carfilzomib in patients with relapsed and/or refractory multiple myeloma who have not been previously treated with bortezomib," said Ravi Vij, M.D., Associate Professor, Department of Medicine,
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... AUSTIN, Texas , July 28, 2014  MedSpring Urgent Care, ... new walk-in clinic at 517 S. Lamar Blvd., Austin, ... urgent care clinic is located on the southeast corner of ... doctor on-site from 9 a.m. - 9 p.m. daily, including weekends ... University of Texas, Central Austin , Anderson ...
(Date:7/28/2014)... ResMed (NYSE: RMD ), innovatore e pioniere ... respiratori del sonno (SDB) e altre patologie croniche del ... il produttore Taiwanese di dispositivi medicali, APEX Medical Corp. ... in testa, che violano i brevetti, utilizzate con l,APEX ... Corte Regionale Distrettuale di Monaco , ...
(Date:7/28/2014)... HILL, N.C. , July 28, 2014   ... of a clinical trial demonstrating that CXL-1427, a novel ... well tolerated in healthy volunteers. The company has now ... in a Phase IIa clinical trial designed to further ... its dosing levels. The Phase I clinical ...
Breaking Medicine Technology:MedSpring Urgent Care opens Barton Springs walk-in clinic in Austin, TX 2ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... -- PharmacyGPO, Inc.,  a pharmacy buying group ... States, today announced a three-year agreement with H. ... (Photo: http://photos.prnewswire.com/prnh/20120507/CG01217 ) Under the ... leading national wholesaler, will be the exclusive supplier ...
... Popular online pharmacy Edens RX ( www.EdensRX.com ) is pleased to ... the month of May. In recognition of Armed Services ... of all the service men and women returning home, military personnel ... to receive $15 off their order. EdensRX.com is known ...
Cached Medicine Technology:PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 3
(Date:7/29/2014)... The National Foundation for Infectious ... ASAE Power of A Silver Award winner for ... encourage everyone age six months and older to be ... for its power to enrich lives through its steady ... and professionals about the importance of vaccination. ...
(Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo campaign for ... embarrassing odors in the office. PoofPad is a discrete bag ... desk drawer. This compact packaging is designed for ease of ... the pad and poof away! , “We’ve all been there. ... appears out of nowhere. It’s embarrassing and unpleasant for everyone ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 "Acceptance, Recognition, ... man who faced his own demons and wants other men ... intended life partner left. A month later, he had no ... longer pay. When Raymond approached the government for assistance, the ... a two-year counselling program. But this approach didn’t get to ...
(Date:7/29/2014)... Current Back2Basics long-term drug rehab ... foot surgery during his first six months of sobriety. ... twice on one foot, once on the other– which was ... foot a year ago and was prescribed drugs that I ... a friend from home who’d recently completed the program. The ...
(Date:7/29/2014)... Consilium Staffing, Your Partner in Locum Tenens, is reporting ... 2014, with strong indications the Irving, Texas-based firm will reach ... , “This is a great time to be at Consilium,” ... , “We are proud of what we have accomplished in ... more excited about how things are shaping up for the ...
Breaking Medicine News(10 mins):Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2Health News:Back2Basics Sober Living Resident Overcomes Obstacle in Early Sobriety 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2
... NEW YORK, May 28 The UltraPulse CO2 fractional ... as an exciting and revolutionary new treatment for ... in a fire as infants told their personal story ... After only two treatments with the groundbreaking ActiveFX and ...
... Results Published in May Issue of Ostomy Wound ... nurses and people living with an ostomy reported ... moldable skin barrier pioneered by ConvaTec Ostomy Care, ... this month in the journal Ostomy Wound ...
... Amex: CXM ) and its subsidiary Tissue ... 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of ... Symposium at the American Society of Gene Therapy (ASGT) ... 2009. Dr. Barbara K. Sosnowski, Cardium,s Vice President ...
... to Vote WHITE Proxy Card to Re-Elect Highly-Qualified ... Opposition SlateTUCSON, Ariz., May 28 The Providence ... announced that it has issued the following letter ... to vote at the upcoming 2009 Annual Meeting ...
... Fla., May 28 As a service to ... PR Newswire will be posting event related news ... into a dedicated event news archive for this ... ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20000306/PRNLOGO ...
... ALISO VIEJO, Calif., May 28 Valeant Pharmaceuticals International ... board of directors has authorized the repurchase of an ... common stock under the securities repurchase program approved in ... repurchase authorization to $500 million from $200 million over ...
Cached Medicine News:Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 2Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 4Health News:Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier 2Health News:Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier 3Health News:Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier 4Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 2Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 3Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 4Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 5Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 6Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 7Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 8Health News:Providence Service Corporation Issues Letter to Stockholders 2Health News:Providence Service Corporation Issues Letter to Stockholders 3Health News:Providence Service Corporation Issues Letter to Stockholders 4Health News:Providence Service Corporation Issues Letter to Stockholders 5Health News:Providence Service Corporation Issues Letter to Stockholders 6Health News:Providence Service Corporation Issues Letter to Stockholders 7Health News:Providence Service Corporation Issues Letter to Stockholders 8Health News:Providence Service Corporation Issues Letter to Stockholders 9Health News:2009 ASCO Annual Meeting and Conference News Distributed by PR Newswire Available at www.EventNewsCenter.com 2Health News:2009 ASCO Annual Meeting and Conference News Distributed by PR Newswire Available at www.EventNewsCenter.com 3Health News:Valeant Announces Increase to Securities Repurchase Program 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: